Which is most important to reducing cardiovascular events: the class of antihypertensive/RDN, or the successful maintenance of blood pressure reduction? 

Ajay J. Kirtane, MD, SM, is a Professor of Medicine at Columbia University Medical Center and Director of the Cardiac Catheterization Laboratories at New York Presbyterian Hospital. Dr. Kirtane is a graduate of Princeton University and Columbia University College of Physicians and Surgeons, and completed his residency in Internal Medicine at the University of California – San Francisco. Dr. Kirtane is a practicing Cardiologist with an interest in coronary and peripheral intervention and assumed the directorship of the NYP/Columbia cardiac catheterization laboratories in 2015. In addition to his clinical commitments at CUMC, Dr. Kirtane has a strong interest in clinical education and research, serving as Chief Academic Officer of the Center for Interventional Vascular Therapy. On the national and international level, he is a co-director of the Cardiovascular Research Foundation’s Transcatheter Cardiovascular Therapeutics meeting, has served as a director of several international, national, and regional educational meetings, and has participated on the program committees for the scientific sessions of both the American College of Cardiology and American Heart Association. Dr. Kirtane’s research interests are in clinical trial methodology and outcomes of device-based and pharmacologic interventions in Interventional Cardiology. He has authored/co-authored >150 original manuscripts and >50 reviews and chapters including the “Coronary Stenting” chapters of the two most widely used textbooks in Interventional Cardiology.